Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT05028504 2023-12-27

ALTER-GO-020

Phase 2 Unknown

86 enrolled

Gynecological Cancer

NCT05885399 2023-06-02

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

Phase 2 Unknown

5 enrolled

CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT05726175 2023-02-13

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Phase 2 Unknown

20 enrolled

Breast

Breast Neoplasms

NCT05519202 2022-08-29

Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer

Phase 2 Unknown

47 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT05485350 2022-08-03

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

32 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05460481 2022-07-20

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Phase 2 Unknown

29 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05244993 2022-07-12

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Phase 2 Unknown

42 enrolled

Breast

Breast Neoplasm Female

NCT04970914 2022-03-08

ALTER-C003

Phase 2 Unknown

32 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Phase 2 Unknown

54 enrolled

Lymphoid

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT05265962 2022-03-04

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Phase 2 Unknown

85 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04952493 2022-01-28

Anlotinib or Penpulimab in Combination With RAI for DTC

Phase 2 Unknown

42 enrolled

Head & Neck

Thyroid Neoplasms

NCT05137171 2021-11-30

AK105 Combined With Anlotinib in Patients With Cervical Cancer

Phase 2 Unknown

36 enrolled

Gynecologic

Uterine Cervical Neoplasms

Clinical Trials

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

ALTER-GO-020

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

ALTER-C003

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Anlotinib or Penpulimab in Combination With RAI for DTC

AK105 Combined With Anlotinib in Patients With Cervical Cancer